MiR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 488-494

  Zhang, Xuelin ^a   Zhu, Jie ^b   Xing, Ruiyun ^b   Tie, Yi ^b   Fu, Hanjiang ^b   Zheng, Xiaofei ^b   Yu, Bingxiang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

A549; A549 CDDP; CCK 8 assay; Chemotherapy; Cisplatin resistance; GSTP1; MiR 513a 3p; MiRNA

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; GLUTATHIONE TRANSFERASE P1; LUCIFERASE; MESSENGER RNA; MICRORNA 513A 3P; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL STRAIN HEK293; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENES, REPORTER; GLUTATHIONE S-TRANSFERASE PI; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUCIFERASES; LUNG NEOPLASMS; MICRORNAS; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 84865173199     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.05.107     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Baunemann Ott C.L., Ratna N., Prayag R., et al. Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba. Curr Oncol 2011, 18(5):e238-e242.
3. Ramalingam S.S., Owonikoko T.K., Khuri F.R. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61(2):91-112.
4. Bunn P.A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why. J Clin Oncol 2002, 20(18 Suppl.):23S-33S.
5. Awasthi S., Sharma R., Singhal S.S., et al. Modulation of cisplatin cytotoxicity by sulphasalazine. Br J Cancer 1994, 70(2):190-194.
6. Robson H., Meyer S., Shalet S.M., et al. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol 2002, 39(6):573-580.
7. Matsumura T., Takigawa N., Kiura K., et al. Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity. In Vivo 2005, 19(4):717-721.
8. Zhang B., Liu M., Tang H.K., et al. The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue squamous cell carcinoma. J Oral Pathol Med 2012, 41(2):141-148.
9. Xia L., Zhang D., Du R., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123(2):372-379.
10. Zhu W., Shan X., Wang T., et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127(11):2520-2529.
11. Li W., Melton D.W. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2011, (September). [Epub ahead of print]. 10.1038/onc.2011.426.
12. Bohanes P., Labonte M.J., Lenz H.J. A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer 2011, 10(3):157-164.
13. Jiao J.W., Tanshinone W.F. IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep 2011, 25(3):781-788.
14. Liu J.L., Wang Y., Jiang J., et al. Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA. Chin Med J 2010, 123(20):2901-2907.
15. Su L., Wang Y., Xiao M., et al. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 110(4):484-491.
16. Min L., Chen Q., He S., et al. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed. Mol Med Rep 2012, 5(1):228-232.
17. Ma J., Lu S., Yu L., et al. FaDu cell characteristics induced by multidrug resistance. Oncol Rep 2011, 26(5):1189-1195.
18. Huang Y., Wang Y., Li Y., et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 2011, 137(5):829-837.
19. Wang J., Zhang J., Zhang L., et al. Expression of P-gp, MRP, LRP, GST-pi and TopoIIalpha and intrinsic resistance in human lung cancer cell lines. Oncol Rep 2011, 26(5):1081-1089.
20. Ishii T., Fujishiro M., Masuda M., et al. A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. Cancer Lett 2004, 212(2):211-223.
21. Huang G., Mills L., Worth L.L. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 2007, 6(5):1610-1619.
22. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9(2):102-114.
23. Zhu W., Zhu D., Lu S., et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012, 29(1):384-391.
24. Yadav S., Pandey A., Shukla A., et al. miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. J Biol Chem 2011, 286(43):37347-43757.
25. Zhu W., Xu H., Zhu D., et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012, 69(3):723-731.
26. Huang Y., Chuang A.Y., Ratovitski E. Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. Cell Cycle 2011, 10(22):3938-3947.
27. Wang Q., Zhong M., Liu W., et al. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2010, 37(7):427-434.
28. Saini S., Yamamura S., Majid S., et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011, 71(19):6208-6219.
29. Alajez N.M., Lenarduzzi M., Ito E., et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011, 71(6):2381-2391.
30. Yoon S., Choi Y.C., Lee S., et al. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett 2010, 584(18):4048-4052.
31. Fu H.J., Zhu J., Yang M., Zhang Z.Y., Tie Y., Jiang H., et al. A novel method to monitor the expression of microRNAs. Mol Biotechnol 2006, 32(3):197-204.
32. Du T., Zamore P.D. microPrimer: the biogenesis and function of microRNA. Development 2005, 132(21):4645-4652.
33. Chen H.C., Cao Y.F., Hu W.X., et al. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China. Dis Markers 2006, 22(3):141-152.
34. Cowell I.G., Dixon K.H., Pemble S.E., et al. The structure of the human glutathione S-transferase pi gene. Biochem J 1988, 255(1):79-83.
35. Wu W., Wang H.D., Guo W., et al. Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res 2010, 29:49.
36. van Zanden J.J., Ben Hamman O., van lersel M.L., et al. Inhibition of human glutathione S-transferase P 1-1 by the flavonoid quercetin. Chem Biol Interact 2003, 145(2):139-148.
37. Lo H.W., Stephenson L., Cao X., et al. Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol Cancer Res 2008, 6(5):843-850.
38. Okamura T., Sinqh S., Buolamwini J., et al. Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem 2009, 284(25):16979-16989.
39. Huang J., Wang Y., Guo Y., et al. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52(1):60-70.
40. Moriya Y., Nohata N., Kinoshita T., et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 2012, 57(1):38-45.
41. Uchida Y., Chiyomaru T., Enokida H., et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 2011, [Epub ahead of print].
42. Bian H.B., Pan X., Yang J.S., et al. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011, 30:20.
43. Krützfeldt J., Rajewsky N., Braich R., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068):685-689.
44. Pan Y., Zhang Y., Jia T., et al. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J 2012, 279(7):1198-1208.